Based on these findings, we confirmed that this compound exhibits excellent anticancer activity in both in vitro and in vivo settings against HER2-overexpressing gastric cancer cells and those exhibiting resistance to trastuzumab. This evidence concerns the gene ERBB2 and gastric cancer.